ALNY
NASDAQ · Biotechnology
Alnylam Pharmaceuticals Inc
$328.16
-3.08 (-0.93%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 2.33B | 1.68B | 7.91B | 8.33B | 7.46B |
| Net Income | -287,876,006 | -186,918,985 | -321,160,759 | -342,544,860 | -322,269,138 |
| EPS | — | — | — | — | — |
| Profit Margin | -12.4% | -11.8% | -4.1% | -4.1% | -4.3% |
| Rev Growth | +38.6% | +38.6% | +6.2% | +0.5% | +0.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 21.10B | 21.10B | 13.62B | 14.01B | 15.59B |
| Total Equity | 572.76M | 572.76M | 22.05B | 23.32B | 23.10B |
| D/E Ratio | 36.85 | 36.85 | 0.62 | 0.60 | 0.67 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -131,492,881 | -90,122,095 | -337,202,257 | -349,941,665 | -268,494,136 |
| Free Cash Flow | — | — | -169,988,534 | -259,812,213 | -171,989,952 |